APO RESEARCH · REPORT
RNAi for Therapeutic
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Product & engineering
Understand the product.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Selected research
Industry Research
RNAi for Therapeutic Industry Research Report 2026
Market perspective
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
Read the full market overview
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
Report Scope
This report quantifies the global RNAi for Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to RNAi for Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
RNAi for Therapeutic Market by Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
RNAi for Therapeutic Segment by Type
siRNA
miRNA
shRNA
RNAi for Therapeutic Segment by Application
Cancer
Cardiovascular
HBV
Others
RNAi for Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNAi for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi for Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of RNAi for Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- siRNA
- miRNA
- shRNA
Applications
- Cancer
- Cardiovascular
- HBV
- Others
Companies covered
- Alnylam Pharmaceuticals
- Arbutus Biopharma (Tekmira)
- Arrowhead
- Dicerna Pharmaceuticals
- Mirna Therapeutics
- Quark Pharmaceuticals
- RXi Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 RNAi for Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 siRNA
- 2.2.3 miRNA
- 2.2.4 shRNA
- 2.3 RNAi for Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Cardiovascular
- 2.3.4 HBV
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 RNAi for Therapeutic Breakdown Data by Type
- 3.1 Global RNAi for Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2027-2032)
4 RNAi for Therapeutic Breakdown Data by Application
- 4.1 Global RNAi for Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global RNAi for Therapeutic Market Perspective (2021-2032)
- 5.2 Global RNAi for Therapeutic Growth Trends by Region
- 5.2.1 Global RNAi for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 RNAi for Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 RNAi for Therapeutic Market Dynamics
- 5.3.1 RNAi for Therapeutic Industry Trends
- 5.3.2 RNAi for Therapeutic Market Drivers
- 5.3.3 RNAi for Therapeutic Market Challenges
- 5.3.4 RNAi for Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top RNAi for Therapeutic Players by Revenue
- 6.1.1 Global Top RNAi for Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global RNAi for Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of RNAi for Therapeutic Head Office and Area Served
- 6.4 Global RNAi for Therapeutic Players, Product Type & Application
- 6.5 Global RNAi for Therapeutic Manufacturers Established Date
- 6.6 Global RNAi for Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America RNAi for Therapeutic Market Size (2021-2032)
- 7.2 North America RNAi for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America RNAi for Therapeutic Market Size by Country (2021-2026)
- 7.4 North America RNAi for Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe RNAi for Therapeutic Market Size (2021-2032)
- 8.2 Europe RNAi for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe RNAi for Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe RNAi for Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific RNAi for Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific RNAi for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific RNAi for Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific RNAi for Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America RNAi for Therapeutic Market Size (2021-2032)
- 10.2 South America RNAi for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America RNAi for Therapeutic Market Size by Country (2021-2026)
- 10.4 South America RNAi for Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa RNAi for Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa RNAi for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa RNAi for Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa RNAi for Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Alnylam Pharmaceuticals
- 12.1.1 Alnylam Pharmaceuticals Company Information
- 12.1.2 Alnylam Pharmaceuticals Business Overview
- 12.1.3 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 12.1.5 Alnylam Pharmaceuticals Recent Developments
- 12.2 Arbutus Biopharma (Tekmira)
- 12.2.1 Arbutus Biopharma (Tekmira) Company Information
- 12.2.2 Arbutus Biopharma (Tekmira) Business Overview
- 12.2.3 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio
- 12.2.5 Arbutus Biopharma (Tekmira) Recent Developments
- 12.3 Arrowhead
- 12.3.1 Arrowhead Company Information
- 12.3.2 Arrowhead Business Overview
- 12.3.3 Arrowhead Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.3.4 Arrowhead RNAi for Therapeutic Product Portfolio
- 12.3.5 Arrowhead Recent Developments
- 12.4 Dicerna Pharmaceuticals
- 12.4.1 Dicerna Pharmaceuticals Company Information
- 12.4.2 Dicerna Pharmaceuticals Business Overview
- 12.4.3 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 12.4.5 Dicerna Pharmaceuticals Recent Developments
- 12.5 Mirna Therapeutics
- 12.5.1 Mirna Therapeutics Company Information
- 12.5.2 Mirna Therapeutics Business Overview
- 12.5.3 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.5.4 Mirna Therapeutics RNAi for Therapeutic Product Portfolio
- 12.5.5 Mirna Therapeutics Recent Developments
- 12.6 Quark Pharmaceuticals
- 12.6.1 Quark Pharmaceuticals Company Information
- 12.6.2 Quark Pharmaceuticals Business Overview
- 12.6.3 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.6.4 Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 12.6.5 Quark Pharmaceuticals Recent Developments
- 12.7 RXi Pharmaceuticals
- 12.7.1 RXi Pharmaceuticals Company Information
- 12.7.2 RXi Pharmaceuticals Business Overview
- 12.7.3 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.7.4 RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 12.7.5 RXi Pharmaceuticals Recent Developments
- 12.8 Silence Therapeutics
- 12.8.1 Silence Therapeutics Company Information
- 12.8.2 Silence Therapeutics Business Overview
- 12.8.3 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.8.4 Silence Therapeutics RNAi for Therapeutic Product Portfolio
- 12.8.5 Silence Therapeutics Recent Developments
- 12.9 Benitec Biopharma
- 12.9.1 Benitec Biopharma Company Information
- 12.9.2 Benitec Biopharma Business Overview
- 12.9.3 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.9.4 Benitec Biopharma RNAi for Therapeutic Product Portfolio
- 12.9.5 Benitec Biopharma Recent Developments
- 12.10 miRagen Therapeutics
- 12.10.1 miRagen Therapeutics Company Information
- 12.10.2 miRagen Therapeutics Business Overview
- 12.10.3 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.10.4 miRagen Therapeutics RNAi for Therapeutic Product Portfolio
- 12.10.5 miRagen Therapeutics Recent Developments
- 12.11 Sylentis
- 12.11.1 Sylentis Company Information
- 12.11.2 Sylentis Business Overview
- 12.11.3 Sylentis Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.11.4 Sylentis RNAi for Therapeutic Product Portfolio
- 12.11.5 Sylentis Recent Developments
- 12.12 Gradalis
- 12.12.1 Gradalis Company Information
- 12.12.2 Gradalis Business Overview
- 12.12.3 Gradalis Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.12.4 Gradalis RNAi for Therapeutic Product Portfolio
- 12.12.5 Gradalis Recent Developments
- 12.13 Sirnaomics
- 12.13.1 Sirnaomics Company Information
- 12.13.2 Sirnaomics Business Overview
- 12.13.3 Sirnaomics Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.13.4 Sirnaomics RNAi for Therapeutic Product Portfolio
- 12.13.5 Sirnaomics Recent Developments
- 12.14 Silenseed
- 12.14.1 Silenseed Company Information
- 12.14.2 Silenseed Business Overview
- 12.14.3 Silenseed Revenue in RNAi for Therapeutic Business (2021-2026)
- 12.14.4 Silenseed RNAi for Therapeutic Product Portfolio
- 12.14.5 Silenseed Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst